Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Fig. 2

Progression-free survival (PFS, a) and overall survival (OS, b) of patients with advanced non-small cell lung cancer (NSCLC) treated with checkpoint inhibitors, stratified for baseline circulating tumor cells (CTC). Median PFS and OS of patients with baseline CTC was significantly shorter than that of patients without CTC (PFS: 1.4 months versus 4.8 months, log rank p < 0.01, OS: 4.5 months versus 12.1 months, log rank p < 0.01)

Back to article page